Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Pharmaceutical industry

Heart failure drug Entresto wins Innovative Product at 2016 UK Prix Galien awards

2016 Prix Galien Award UK winners

Source: Prix Galien

Front, from left. Karen Westaway chief executive of ValueBase Healthcare; Sir Michael Rawlins, chair of the Prix Galien judging panel; Sir Kevin Barron, parliamentary sponsor; Alison Currie, clinical director at ValueBase Healthcare. Back, from left: representatives from Astellas, winners of the Real World Evidence Award with Dificlir; Chiesi, winners of the Orphan Product Award with Holoclar; and Novartis, winners of the Innovative Product Award with Entyvio

Novartis has scooped one of the top 2016 UK Prix Galien Awards, considered to be the highest accolades that can be awarded to a pharmaceutical product.

The Innovative Product Award was given to its heart failure treatment, Entresto (sacubitril/valsartan), the first new treatment for the condition in 15 years, Novartis’ fourth UK Prix Galien medal since 2002.

Chiesi’s Holoclar and Astellas’ Dificlir were also recognised at the ceremony, which was held at the House of Commons in London on 21 September 2016. 

Chiesi’s Holoclar — Europe’s first approved stem cell therapy for moderate-to-severe forms of limbal stem cell deficiency (LSCD), a rare eye condition that can lead to blindness — was given the Orphan Product Award. 

Astellas was awarded a Real World Evidence Award for its Clostridium difficile treatment, Dificlir (fidaxomicin), which launched in 2012 and received a previous Prix Galien commendation in 2014.

Prix Galien Awards take place in 17 countries across the world and there is an international event every two years, but this year the UK was the first country to issue the Real World Evidence Award. 

Sir Michael Rawlins, chair of the UK Prix Galien judging panel, comments: “A unique series of local service evaluations were conducted in 2013—2014 to evaluate the impact of Dificlir introduction on the NHS. The evaluation, studied in real-world settings, included investigating its effects on service delivery, the management of CDI and its costs, primarily to inform local decision-making.

“Results indicated the very significant contribution that Dificlir’s use can make to tackling the major public health problems of antimicrobial resistance through targeted antibiotic therapy and infection control,” he adds.

The 2016 UK awards received a record number of entrants, 16 of which were shortlisted. 

The Prix Galien was created in France in 1970 by pharmacist Roland Mehl to promote advances in pharmaceutical research. 


Citation: The Pharmaceutical Journal URI: 20201759

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • 2016 Prix Galien Award UK winners

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.